Also Known As: Saxagliptin, Onglyza

Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.[1] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. It was based on a drug development program with 8 randomized trials: 1 phase 2 dose-ranging (2.5–100 mg/d) study; 6 phase 3, 24-week controlled trials with additional controlled follow-up from 12 to 42 months, double-blinded throughout; and one 12-week mechanism-of-action trial with a 2-year follow-up period.[2] In June 2008, it was announced that Onglyzawould be the trade name under which saxagliptin will be marketed.[3]

The FDA approved Saxagliptin with brand name Onglyza on July 31, 2009.[4]

Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP[5] and the degradation of GLP-1.[5][6]

Bristol-Myers Squibb announced on 27 December 2006 that Otsuka Pharmaceutical Co. has been granted exclusive rights to develop and commercialize the compound in Japan. Under the licensing agreement, Otsuka will be responsible for all development costs, but Bristol-Myers Squibb retains rights to co-promote saxagliptin with Otsuka in Japan.[7] Further, on 11 January 2007 it was announced that Bristol-Myers Squibb and AstraZeneca would work together to complete development of the drug and in subsequent marketing.[8]

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Complete a survey on Saxagliptin to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.